Teva and Blackstone Fund $400M to Advance duvakitug Clinical Growth
Teva Pharmaceuticals and Blackstone Life Sciences have agreed on a substantial $400 million strategic funding collaboration designed to advance duvakitug through crucial clinical development phases. The agreement, which spans four years, aims to support phase 3 studies of the promising duvakitug treatment for ulcerative colitis and Crohn’s disease. Teva is executing its Pivot to Growth strategy by expanding innovative assets like duvakitug, while Blackstone solidifies its role as a key biopharmaceutical investor with a strong focus on transformative therapies.
PARSIPPANY, N.J., and CAMBRIDGE, Mass. — Teva Pharmaceuticals, a U.S. branch of Teva Pharmaceutical Industries Ltd., and funds managed by Blackstone Life Sciences (BXLS) today announced a $400 million funding cooperation to advance duvakitug’s clinical development globally. The capital infusion will be distributed over the next four years and lays the groundwork for further regulatory and commercial progress.
Under the agreement’s terms, BXLS will provide the capital to accelerate duvakitug’s clinical progress with eligibility for future milestone payments and low single-digit royalties upon duvakitug’s regulatory approval and commercial sales. Although the therapy is still in clinical evaluation, both companies believe that duvakitug has the potential to significantly impact patients with unmet medical needs.
Evan Lippman, Executive Vice President of Business Development at Teva, stated that the deal represents a meaningful step in transforming strategy into action under the company’s Pivot to Growth initiatives. He emphasized that disciplined, capital-efficient alliances enable Teva to bolster its innovative pipeline while safeguarding the company’s financial strength and resilience.
Duvakitug is a human monoclonal antibody that targets the TL1A pathway, a promising mechanism believed to be involved in inflammation and fibrosis associated with inflammatory bowel diseases. Monoclonal antibody (mAb) therapies are used to treat various conditions, such as cancer, autoimmune disorders, and metabolic illnesses. The treatment is currently undergoing phase 3 clinical studies for ulcerative colitis and Crohn’s disease, two debilitating forms of inflammatory bowel disease that affect millions of patients worldwide.
BXLS leadership also expressed enthusiasm about the collaboration. Dr. Nicholas Galakatos, Global Head of BXLS, noted that the partnership underscores the platform’s dedication to supporting high-priority assets like duvakitug, which could provide meaningful clinical benefit. Paris Panayiotopoulos, Senior Managing Director at BXLS, added that they view duvakitug as a potential best-in-class therapy in a growing therapeutic space.
This funding agreement aligns with Teva’s Pivot to Growth strategy, which focuses on delivering innovative treatments and expanding Teva’s presence in immunology and other therapeutic areas. The strategy also emphasizes sustained financial discipline through capital-efficient partnerships. This approach, according to company statements, will drive long-term shareholder value while bringing transformative medicines to patients.
The duvakitug program began early clinical development several years ago and has since progressed through interim studies. Phase 2b results have shown encouraging maintenance data demonstrating durable clinical efficacy in both ulcerative colitis and Crohn’s disease populations, providing a strong foundation for ongoing phase 3 trials.
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic autoimmune disorder that causes recurring inflammation in the gastrointestinal tract. Globally, approximately 4.9 million patients are diagnosed with IBD, and disease incidence is rising in many regions. Common symptoms include persistent diarrhea, abdominal pain, rectal bleeding, appetite loss, and unexplained weight loss.
Despite the availability of several existing treatments, there remains a significant unmet need for more effective and durable therapeutic options that can reduce inflammation and slow disease progression. Teva and Sanofi previously announced a separate collaboration to co-develop and, upon regulatory approval, co-commercialize duvakitug worldwide, reinforcing the therapy’s potential reach and impact.
Financially, the agreement offers a blend of immediate support and future revenue potential for both partners. Teva benefits from upfront capital to fund ongoing trials, while BXLS may receive milestone and royalty payments if duvakitug is approved and successfully launched in key markets, including the U.S. and Europe.
The announcement also reflects broader industry trends of large pharmaceutical companies partnering with private investment platforms to share risk and accelerate drug development. These strategic alliances allow biopharmaceutical companies to maintain momentum in critical late-stage programs like duvakitug while preserving capital for other research priorities.
In conclusion, Teva and Blackstone Life Sciences’ $400 million funding pact marks a pivotal moment in advancing duvakitug’s clinical development. With phase 3 trials underway and the potential to address unmet needs in ulcerative colitis and Crohn’s disease, both partners are positioned to deliver meaningful benefits to the IBD patient community. Continued collaboration and future regulatory milestones will determine duvakitug’s path to market approval and global patient access.
